Everything tagged "abbv" across research, earnings, and macro.
3 articles
AbbVie is showing that its post-Humira rebuild is real, with Skyrizi and Rinvoq driving strong growth and full-year guidance moving higher. Heavy debt and a negative equity position remain the main risks, but cash flow and earnings power still look compelling.
AbbVie Inc. (ABBV) rises after announcing a $10.9 billion all-cash acquisition of Apogee Therapeutics. The deal expands AbbVie’s immunology pipeline and reinforces its post-Humira growth strategy, while strong recent earnings and raised guidance add support to the rally.
A packed earnings slate will test whether investors still have room for premium-priced leaders. GE Aerospace, UnitedHealth, RTX, Tesla, Intel, and GE Vernova headline a week that could reveal demand trends, margin pressure, and how much perfection is already in the price.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator